The United States government has acquired a 9.9% passive equity stake in Intel, purchasing 433.3 million shares at $20.47 each, roughly $4 below the company’s closing price of $24.80, using $5.7 billion from previously allocated CHIPS Act grants and $3.2 billion from the Secure Enclave initiative. This brings total federal support for Intel to $11.1 billion when combined with the $2.2 billion in grants already received.
The deal includes a five‑year warrant at $20 per share for up to an additional 5% stake, exercisable only if Intel’s foundry business falls below 51% ownership. The government will not have board representation nor governance or information rights, and will vote in alignment with Intel’s board, with certain exceptions.
US government announces 10% stake in Intel
The investment highlights the Trump administration’s strategic push to bolster domestic semiconductor production through equity rather than traditional subsidies. It marks a notable shift in US industrial policy toward state-linked capital deployment in private startups.
Critics warn of weakened corporate governance. The government’s passive stake may dilute the rights and protections of minority shareholders, especially under Delaware law, since sovereign immunity limits legal recourse. Others argue the deal undermines free-market norms and may introduce political priorities into technology development decisions.
Proponents emphasise the strategic benefit: Intel, historically a leading-edge logic R&D and manufacturing firm in the US, receives a lifeline to modernise capacity and reduce reliance on external foundries. Intel’s stock jumped approximately 5–7% on the announcement.
Intel CEO Lip-Bu Tan retains control despite recent pressure from the White House over ties to China and a demanded resignation. The equity deal followed after he secured a meeting with the president. The move also aligns with similar equity-based interventions in other high-tech firms, signalling a broader trend toward state influence in strategic sectors.
For Intel, the injection supports an aggressive US expansion plan, including new fab facilities. It provides crucial funding stability, though the long-term impact will depend on the firm’s resurgence against competitors such as AMD and TSMC.
